Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Ferrajoli A, O'Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ.
Ferrajoli A, et al. Among authors: lerner s.
Cancer. 2003 Aug 15;98(4):773-8. doi: 10.1002/cncr.11551.
Cancer. 2003.
PMID: 12910522
Free article.
Clinical Trial.